|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 184 Liberty Corner Rd |
Address2 |
|
| City | Warren |
State | NJ |
Zip Code | 07059 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401107178-53816
|
||||||||
|
6. House ID# 558670001
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Hailey Ray |
Date | 4/20/2026 12:47:50 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
General review and monitoring of legislative and administrative actions related to the design, development, and deployment of artificial intelligence platforms, especially as related to healthcare, over the counter settings, and protection of personally identifiable information.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
General monitoring of issues and administrative action related to intellectual property protection.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
General monitoring of legislative and administrative action related to health care policy; including the reauthorization of the OTC Monograph Drug User Fee Program (OMUFA);
S.3122 - Better FDA Act of 2025
S.2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
S.3677 - Dietary Supplement Listing Act of 2026
H.R. 6868 - ACCESS Through OTC Innovation Act
General monitoring and review of implementation of Title V of H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, specific to Over-the-Counter Monograph Drug User Fee Amendments.
General monitoring of legislative and administrative action related to womens health issues;
General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products;
General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues;
General monitoring of legislative and administrative action related to FDA monograph reform and user fees;
General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications;
Review of coverage for medically necessary services in Medicare and Medicare Advantage;
Review of legislation impacting the Dietary Supplement Health and Education Act of 1994;
General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options; and
General monitoring and review of Executive Order 14273, particularly section 9(b) as related to improvements to the process through which prescription drugs can be reclassified as over-the-counter medications, including recommendations to optimally identify prescription drugs that can be safely provided to patients over the counter.
Monitoring and review of federal rulemaking processes on Increasing Access to Nonprescription Drugs.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Treasury - Dept of, Centers For Medicare and Medicaid Services (CMS), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
General monitoring of legislative and administrative action related to Medicare and Medicaid policy, including changes in coverage/eligibility, including H.R. 1;
General monitoring of Medicare/MA coverage of dental services; and
General review of legislation and rulemaking impacting dual eligible enrollees.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
General monitoring of Issues related to federal tax amortization of research and development expenses;
General review and monitoring of legislation that includes over-the-counter dietary supplement products, specifically multivitamins, as qualified medical expenses;
General review and monitoring of legislation and administrative action related to oral healthcare products, including specialty toothpastes and rinses, as qualified medical expenses under HSA/FSA;
General review and monitoring of implementation of One Big Beautiful Bill Act (OBBBA)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of, Internal Revenue Service (IRS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Monitor and review of issues related to the Section 301 tariffs;
Monitor and review of issues related to the Section 232 tariffs;
Monitor and review of issues related to reciprocal tariffs under International Economic Emergency Powers Act;
General monitoring and review of Executive Order 14257 and impacts on OTC products;
General monitoring and review of legislative and executive actions on international trade policy related to tariffs, import/export concerns;
General monitoring of legislative and administrative action related to review of the United States-Mexico-Canada Agreement (USMCA); and
General review and monitoring of global supply chain concerns
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
General monitoring and review of issues and executive actions related to or impacting multivitamins and nutrition.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FAM
16. Specific lobbying issues
General review of legislative and administration action related to pediatric over-the-counter medication concerns.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
General review and monitoring of processes impacting over-the-counter switches.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
General review and monitoring on efforts aimed at preventing youth consumption of tobacco products;
General review and monitoring of smoking cessation and over-the-counter alternatives for adult consumers.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
General issues related to the manufacturing and supply chain resiliency of over-the-counter medications, specifically as it relates to additional domestic production of healthcare products;
General monitor and review of legislative and administrative action related to domestic supply chain and manufacturing capabilities.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
General monitoring of legislative and administrative action related to sustainability, particularly related to packaging and consumables.
General monitoring and review of legislative and administration actions related to water consumption, particularly initiatives aimed at reducing water use or increasing savings.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOR
16. Specific lobbying issues
General review and monitoring of U.S. diplomatic relations.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jonathan |
Martinez |
|
|
|
Hailey |
Ray |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
The ultimate parent entity, Haleon, disclosed on Form LD-1, has an interest in the issues lobbied
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |